These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
doi: 10.1016/j.jtemb.2015.07.002 109 KocakMAkarsuEKorkmazHTaysiS
Key Benefits of GHK-Cu Peptide: Quantitative Evidence of Transformation GHK-Cu has a strong research and anecdotal evidence base in the anti-aging category
DSIP Research and Chronic Pain Managing chronic pain is challenging, as standard medications such as anti-inflammatory drugs and opioids often carry risks when used for extended periods
beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas